## Exhibit 8 Showing of patent claims, documenting manner claims read on Approved Product ORAQIX

Claim	Claim Limitation	ORAQIX Product Composition
Claim 1	The pharmaceutical composition comprising:	
	(i) one or more local anaesthetics in oil form;	See package insert, Exhibit 1: "lidocaine and prilocaine," "in oil phase"
	(ii) one or more surfactants in an amount effective to produce a homogenous formulation wherein, at least one surfactant has thermoreversible gelling properties; and	"Poloxamer excipients" having reversible temperature-dependant gelation
	(iii) water; wherein said composition is in the form of an emulsion or microemulsion and has	"Purified water"
	thermoreversible gelling properties such that said composition is less viscous at room temperature than after introduction onto a mucous membrane of a patient.	"Gelation occurs at body temperature"
Claim 3	The pharmaceutical composition according to claim 1, wherein said one or more local anaesthetics are present in an amount of 0.5-20% by weight based on the total weight of the composition.	See Composition, Exhibit 4: 50 mg of lidocaine/prilocaine to 1000 mg is 5% of total weight of composition
Claim 4	The pharmaceutical composition according to claim 3, wherein said one or more local anaesthetics are present in an amount of 2-7% by weight based on the total weight of the composition.	See Composition, Exhibit 4: 50 mg of lidocaine/prilocaine to 1000 mg is 5% of total weight of composition
Claim 5	The pharmaceutical composition according to claim 1, wherein said one or more local anaesthetics is a eutectic mixture of local anaesthetics.	See package insert, Exhibit 1: which states a mixture of lidocaine and prilocaine is a "eutectic mixture."

Claim 6	The pharmaceutical composition according to claim 5, wherein said one or more local anaesthetics is a eutectic mixture of lidocaine and prilocaine.	See package insert, Exhibit 1: which states a mixture of lidocaine and prilocaine is a "eutectic mixture."
Claim 8	The pharmaceutical composition according to any one of claims 1-7, comprising more than one surfactant of which at least one is a surfactant having thermoreversible gelling properties.	See package insert, Exhibit 1: the gel contains thermosetting agents (Poloxamer 188 and Poloxamer 407) and said excipiants show reversible temperature dependant gelation.
Claim 9	The pharmaceutical composition according to any one of claims 1-7, wherein the total amount of surfactant is present in an amount of up to 50% by weight based on the total weight of the composition.	See Composition, Exhibit 4: 210 mg poloxamers in 1000 mg of composition is 21% by weight.
Claim 11	The pharmaceutical composition according to claim 10, wherein the surfactant is a poloxamer.	See Composition, Exhibit 4
Claim 12	The pharmaceutical composition according to any one of claims 1-7, comprising the two surfactants Poloxamer 188® and Poloxamer 407®.	See Composition, Exhibit 4
Claim 16	The composition of claim 1, wherein said one or more local anesthetics comprise 0.5 to 20% of the final weight of said composition, and said one or more surfactants comprise up to 50% of the final weight of said composition.	See Composition, Exhibit 4